Search Results
Your search for ,pER matches 3965 pages
Showing 601 - 650High-Temporal/High-Spatial Resolution Breast MRI for Patients With High Background Parenchymal Enhancement
In a single-center retrospective study reported in the Journal of Clinical Oncology, Eskreis-Winkler et al found that contrast-enhanced magnetic resonance imaging (MRI) using a high-temporal/high-spatial resolution (HTHS) protocol improved breast cancer detection and reduced unnecessary biopsies vs ...
Patterns in Early-Onset Cancer Incidence in the United States From 2010 to 2019
In a study using SEER (Surveillance, Epidemiology, and End Results) registry data reported in JAMA Network Open, Koh et al found that the incidence of cancer among individuals in the United States younger than age 50 years—defined as early-onset cancer—increased significantly between 2010 and 2019. ...
Breast Cancer Screening and 10-Year Net Survival in Canadian Women Aged 40 to 49
In a Canadian study reported in the Journal of Clinical Oncology, Wilkinson et al found that breast cancer screening was associated with greater 10-year breast cancer net survival among women aged 40 to 49 living in jurisdictions including mammography screening programs for this age group, compared ...
Radiation Facility Volume and Survival in Very High–Risk Prostate Cancer Treated With Curative Radiation and Androgen-Deprivation Therapy
In a U.S. retrospective cohort study reported in JAMA Network Open, Sebastian et al found that treatment at a high-volume radiation facility was associated with improved overall survival among men with very high–risk prostate cancer receiving curative-intent radiotherapy with androgen-deprivation...
Do MDS Diagnoses Require Second Opinions?
Investigators have identified a need for strong coordination between clinicians and skilled pathologists to ensure accurate, timely diagnosis of myelodysplastic syndromes (MDS). The study findings were recently published by Gorak et al in Blood Advances. Background MDS—a collection of chronic...
CLEAR Trial: Continued Survival Benefit With First-Line Lenvatinib Plus Pembrolizumab in Advanced Kidney Cancer
At extended follow-up, lenvatinib plus pembrolizumab showed sustained superiority over sunitinib for overall and progression-free survival as first-line treatment for advanced renal cell carcinoma.1 The majority of the benefit was observed in intermediate- and poor-risk subgroups, according to the...
FDA Approves Melphalan Hepatic Delivery System for Adult Patients With Unresectable Hepatic-Dominant Metastatic Uveal Melanoma
On August 14, the U.S. Food and Drug Administration (FDA) approved the HEPZATO KIT, a melphalan hepatic delivery system, as a liver-directed treatment for adult patients with metastatic uveal melanoma and unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic...
Study Shows Activity of Talquetamab in Highly Refractory Multiple Myeloma
In the phase I/II MonumenTAL-1 trial, the novel bispecific antibody talquetamab produced responses in more than 70% of heavily pretreated patients with multiple myeloma.1 Of note, the safety profile confirmed results of the phase I portion of the study (recently published in TheNew England Journal...
Ruxolitinib Demonstrates Clinical Activity in a Phase II Trial of Chronic Myelomonocytic Leukemia
In a phase II trial, treatment with the JAK2 inhibitor ruxolitinib resulted in clinical activity in two-thirds of patients with chronic myelomonocytic leukemia (CMML) with splenomegaly or an otherwise high disease symptom burden. The magnitude of symptomatic benefit was similar to that observed in...
SWOG S1826: Nivolumab Plus AVD Surpasses Standard-of-Care Combination Regimen in Patients With Advanced Hodgkin Lymphoma
The addition of nivolumab, an immune checkpoint inhibitor, to chemotherapy significantly improved progression-free survival in adults and children with advanced classical Hodgkin lymphoma with reduced toxicity compared with standard-of-care brentuximab vedotin plus chemotherapy, according to the...
Vigorous Intermittent Lifestyle Physical Activity and Cancer Incidence Among Nonexercising Adults
In an analysis from the UK Biobank Accelerometry Study reported in JAMA Oncology, Stamatakis et al found that bouts of vigorous intermittent lifestyle physical activity were associated with reduced risk of cancer among nonexercising adults. Vigorous intermittent lifestyle physical activity refers...
Homoharringtonine-Based Induction in Pediatric AML
In a Chinese study (CCLG-AML 2015) reported in the Journal of Clinical Oncology, Li et al found that homoharringtonine (HHT)-based induction therapy was associated with promising outcomes in pediatric acute myeloid leukemia (AML). As stated by the investigators, “HHT is commonly used for the...
AI-Supported Screen Reading vs Standard Double Reading in Mammography Screening for Breast Cancer
In a Swedish study (Mammography Screening with Artificial Intelligence [MASAI]) reported in The Lancet Oncology, Lång et al found that artificial intelligence (AI)-supported screen reading was associated with a similar cancer detection rate and a lower screen-reading workload vs standard double...
FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
On August 11, the U.S. Food and Drug Administration (FDA) approved the fixed-dose combination of niraparib and abiraterone acetate (Akeega), with prednisone, for adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer, as determined by...
Alcohol Consumption and Risk of Breast Cancer Recurrence
A report published by Kwan et al in the journal Cancer provides new information that may help oncologists answer one of the most common questions they hear from breast cancer survivors: Is it safe to drink alcohol? The findings suggest drinking alcohol is not associated with an increased risk of...
Does Daily Consumption of Sugar-Sweetened Beverages Increase the Risk of Liver Disease Among Postmenopausal Women?
Approximately 65% of adults in the United States consume sugar-sweetened beverages daily. Researchers led a study examining the associations among intake of sugar-sweetened or artificially sweetened beverages and the incidence of liver cancer and chronic liver disease mortality in a large cohort of ...
Should CDK4/6 Inhibitors Be a First-Line Option for Advanced Hormone Receptor–Positive, HER2-Negative Breast Cancer?
Two studies presented at the 2023 ASCO Annual Meeting challenge the use of CDK4/6 inhibitors as part of upfront treatment of advanced hormone receptor–positive, HER2-negative breast cancer. The first, the SONIA trial, found that first-line treatment with CDK4/6 inhibitors led to greater toxicity...
Translating Consent Documents: Potential Barrier for Including Underrepresented Groups in Clinical Trials
Cancer research centers conducting clinical trials could potentially enroll more patients from underrepresented racial and ethnic groups by placing a greater emphasis on relieving investigators of the costs of translating consent documents into languages other than English, according to a study...
Neoadjuvant FOLFOX vs Chemoradiotherapy in Locally Advanced Rectal Cancer
As reported in The New England Journal of Medicine by Deb Schrag, MD, MPH, FASCO, and colleagues, the phase III PROSPECT trial has shown neoadjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) was noninferior in disease-free survival vs chemoradiotherapy among patients with locally advanced...
Researchers May Have Uncovered Two New Subtypes of HPV-Positive Head and Neck Squamous Cell Carcinomas
Human papillomavirus (HPV)–positive head and neck squamous cell carcinomas can be divided into two distinct subtypes that may help determine how well patients will respond to therapy, according to a novel study published by Schrank et al in PNAS. The findings also identified a new mechanism of HPV...
Exercise May Reduce Sexual Dysfunction Caused by Prostate Cancer Treatment
A combination of resistance and aerobic exercise may improve sexual function in patients with prostate cancer, according to a new study conducted in Australia. The research was presented by Galvao et al at the 2023 ASCO Breakthrough meeting (Abstract 71) in Yokohama, Japan. “Sexual dysfunction is a ...
IMerge Trial: Use of Imetelstat Reduces Transfusion Dependence in Lower-Risk MDS
In the primary analysis of the phase III randomized, double-blind, placebo-controlled IMerge trial, in those achieving the primary endpoint of 8-week transfusion independence, treatment with imetelstat significantly reduced transfusion dependence—for a median duration of 1 year—and improved a...
Short Bursts of Vigorous Daily Activity May Be Linked to Reduced Cancer Incidence
Investigators have found that just 4.5 minutes of vigorous activity per day could reduce the risk of some cancer types by up to 32%. The results of the recent study were published by Stamatakis et al in JAMA Oncology. Background Vigorous intermittent lifestyle physical activity describes very...
Patients in Lower-Income Communities May Be Less Likely to Receive CT Colonography Than Those in Higher-Income Communities
Patients who reside in lower-income communities may be less likely to undergo colorectal cancer screenings with computed tomography (CT) colonography than those who reside in higher-income communities, according to a new study published by Christensen et al in the American Journal of ...
Reasons for Nonparticipation in a Colorectal Cancer Screening Trial Comparing Outcomes With Colonoscopy vs FIT
In an analysis reported in JAMA Network Open, Robertson et al found U.S. veterans most frequently cited a preference for stool testing as a reason for declining participation in the CONFIRM trial, which compared the effect on colorectal cancer mortality with annual colonoscopy vs annual fecal...
Modeled Effects of Reducing the Recommended Screening Age for Colorectal Cancer in Canada
In a modeling study reported in JAMA Oncology, Kalyta et al found that reducing the starting age for colorectal cancer screening with the biennial fecal immunochemical test (FIT) in Canada would result in reduction in colorectal cancer burden at a “modest cost.” As stated by the investigators:...
Addition of Nivolumab to SABR in Early-Stage or Isolated Lung Parenchymal Recurrent NSCLC
In the phase II I-SABR trial reported in The Lancet, Chang et al found that the addition of nivolumab to stereotactic ablative radiotherapy (SABR) improved event-free survival in patients with previously untreated stage I or II or isolated parenchymal recurrent node-negative non–small cell lung...
Roundup of Abstracts on New Therapies for Gastrointestinal Cancers From ASCO 2023
The 2023 ASCO Annual Meeting featured thousands of abstracts. In addition to our in-depth coverage of pivotal research from the meeting, The ASCO Post highlights the following studies of novel therapies for gastrointestinal cancers. Addition of Anti-TIGIT Agent in Unresectable Liver Cancer In the...
Implementation of Pediatric Early Warning Systems in Resource-Limited Latin American Hospitals
In a study reported in The Lancet Oncology, Agulnik et al found that implementation of pediatric early warning systems resulted in reduced clinical deterioration event mortality among children with cancer in resource-limited hospitals in Latin America. Study Details The Proyecto Escala de...
Investigators Offer Guidance for Improving Access to Oncology Drugs in Sub-Saharan Africa
Investigators have addressed the need to improve access to oncology drugs designed to increase the survival and quality of life of patients in sub-Saharan Africa and combat the significant health-care disparities many of these patients continue to face, according to a new study published by Sharma...
Diversity May Play a Key Role in Black Patients’ Trust of Videos About Prostate Cancer
Black patients may be 1.6 times more likely to believe medical information presented by a Black speaker than information presented by a White speaker, according to a new study published by Loeb et al in JAMA Network Open. The findings highlight the importance of increasing racial diversity among...
Damon Runyon Names Physician-Scientist Awardees
Three scientists who are researching novel approaches to the treatment of cancer have been named the 2023 recipients of the Damon Runyon Physician-Scientist Training Award: Nicole M. Cruz, MD; Mounica Vallurupalli, MD; and Nina Weichert-Leahey, MD. The awardees were selected through a highly...
In Ovarian Cancer, Neoadjuvant Olaparib Feasible, Appears Effective in Pilot Study Among Patients With BRCA Mutation
Encouraging outcomes were achieved in patients with BRCA-mutated ovarian cancer who received neoadjuvant treatment with olaparib in a feasibility study led by Shannon N. Westin, MD, MPH, Professor in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD...
Study Examines Impact of Modified Treatment Protocols on Survival in Pediatric Patients With ALL
The 5-year survival rate of pediatric patients with acute lymphoblastic leukemia (ALL) has continued to increase to 94%, according to a new study published by Pieters et al in the Journal of Clinical Oncology. Background ALL is the most common form of pediatric cancer in the Netherlands—with about...
Aspartame Hazard and Risk Assessment Results Released by IARC and JECFA
Assessments of the health impacts of the nonsugar sweetener aspartame were released today by the International Agency for Research on Cancer (IARC) and the World Health Organization (WHO)/Food and Agriculture Organization (FAO) Joint Expert Committee on Food Additives (JECFA). Citing “limited...
Crenigacestat Plus BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma
In a single-institution, phase I, first-in-human trial reported in The Lancet Oncology, Cowan et al found that the combination of the γ-secretase inhibitor (GSI) crenigacestat and B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy was tolerable and produced a high...
Functional Recovery and Quality of Life in Older Patients Undergoing Colorectal Cancer Surgery
In a study of real-world prospective data—GOSAFE—reported in the Journal of Clinical Oncology, Montroni et al found that the majority of patients aged ≥ 70 years undergoing colorectal cancer surgery showed maintained or improved quality of life and achieved functional recovery during follow-up....
Changing How Immune Checkpoint Inhibitors Are Delivered Could Reduce Costs by 14%, Study Finds
Investigators have found that millions of dollars could be saved annually across the Veterans Health Administration by reconsidering how immune checkpoint inhibitors are delivered, according to a new study published by Bryant et al in Health Affairs. The findings suggested that if vials of immune...
Assessing Geriatric Oncology Practice in Portugal
The global population is aging rapidly. Currently, there are more than 703 million people worldwide aged 65 and older, representing 9.1% of the global population. It is estimated that this percentage will grow to 15.9%—1.5 billion people—by 2050.1 And with that growing aging population will come...
Lobular vs Ductal Breast Cancer: Distinctions in Management
As a relatively rare subtype, lobular breast cancer is not well understood by many oncologists. At the 2023 Miami Breast Cancer Conference, Tari A. King, MD, FASCO, described how it differs from its more common counterpart, ductal breast cancer, in terms of characteristics, prognosis, and optimal...
CLEAR Trial: Continued Survival Benefit With First-Line Lenvatinib Plus Pembrolizumab in Advanced Kidney Cancer
At extended follow-up, lenvatinib plus pembrolizumab showed sustained superiority over sunitinib for overall and progression-free survival as first-line treatment for advanced renal cell carcinoma.1 The majority of the benefit was observed in intermediate- and poor-risk subgroups, according to the...
SWOG S1826: Nivolumab Plus AVD Surpasses Standard-of-Care Combination Regimen in Patients With Advanced Hodgkin Lymphoma
The addition of nivolumab, an immune checkpoint inhibitor, to chemotherapy significantly improved progression-free survival in adults and children with advanced classical Hodgkin lymphoma with reduced toxicity compared with standard-of-care brentuximab vedotin plus chemotherapy, according to the...
Association of Alcohol Intake With Risk of Early-Onset Colorectal Cancer
In a Korean study reported in the Journal of Clinical Oncology, Jin et al found that increased alcohol intake may be associated with an increased risk of early-onset colorectal cancer. Study Details The study involved data from 5,666,576 individuals aged 20 to 49 years from the Korean National...
First-Line FOLFOXIRI Plus Cetuximab or Bevacizumab in BRAF V600E–Mutant Metastatic Colorectal Cancer
In the German phase II FIRE-4.5 trial reported in the Journal of Clinical Oncology, Stintzing et al found that the addition of cetuximab vs bevacizumab to FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) did not improve objective response rate in the first-line treatment of...
Comparison of Conditioning Treatments in Patients With AML Undergoing HLA-Haploidentical Hematopoietic Stem Cell Transplant
In a Chinese phase III trial reported in the Journal of Clinical Oncology, Ling et al found that conditioning with busulfan/fludarabine resulted in reduced transplantation-related mortality vs busulfan/cyclophosphamide in patients with acute myeloid leukemia (AML) undergoing human leukocyte antigen ...
CDCP1 May Be an Effective Therapeutic Target for Patients With Metastatic Bladder Cancer
Researchers have identified a new potential therapeutic target—the cell-surface tumor antigen CUB domain–containing protein 1 (CDCP1)—for patients with all subtypes of metastatic bladder cancer, according to findings presented by Chopra et al at the Society of Nuclear Medicine & Molecular...
Risk of Ovarian Cancer in Postmenopausal Patients With Polycystic Ovary Syndrome
Patients with polycystic ovary syndrome may not have a higher risk of ovarian cancer than those without the condition; however, postmenopausal patients with polycystic ovary syndrome may have twofold the risk of developing ovarian cancer, according to recent findings presented by Frandsen et al at...
Risk-Adapted Neoadjuvant Chemoradiotherapy in Rectal Cancer
A report from the German OCUM study published by Ruppert et al in the Journal of Clinical Oncology details long-term locoregional recurrence outcomes with risk-adapted neoadjuvant chemoradiotherapy plus total mesorectal excision and total mesorectal excision alone in patients with rectal cancer....
Use of Eltrombopag in Low-Risk Myelodysplastic Syndrome With Thrombocytopenia
Interim results of a phase II study (EQOL-MDS) reported in the Journal of Clinical Oncology by Oliva et al showed that eltrombopag, an orally bioavailable small molecule acting as a thrombopoietin receptor agonist, significantly increased the rate of platelet response vs placebo in patients with...
Endometrial Cancer Risks and Trends Among Different Populations of African Descent
Women of African descent may have an elevated risk of being diagnosed with advanced endometrial cancer and developing aggressive tumors compared with White women, according to a recent study published by Medina et al in Cancer. Background Endometrial cancer is classified as endometrioid or the more ...
